Medical International Technology (MIT), a developer of needle free injectors, has received Chinese State Food and Drug Administration (SFDA) approval and license to sell MED-JET products in China.
MIT provides a safe and effective means to help prevent the spread of deadly diseases to both humans and animals through the use of the Med-Jet and Agro-Jet needle-free injection system.
MIT president and CEO Karim Menassa said they are delighted to have received the official certification to sell MED-JET products to the largest human medical market in the world," Menassa said.
"We can execute our business plan, which forecasts multi million dollars of sales in different niche markets as well as hospitals and clinics across all Chinese provinces.
MIT Canada vice-president and chief strategy officer Francis Bellido believes that access to the Chinese market, with its growing middle class population demanding more quality healthcare, could be instrumental for MIT due to the huge volume of needle-free injectors needed to satisfy the staggering Chinese demand.